サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1575127

体外診断向け受託製造の市場規模、シェア、動向分析レポート：製品別、サービス別、技術別、最終用途別、地域別、セグメント予測、2024年～2030年

In Vitro Diagnostics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Instruments, Software & Services), By Service, By Technology, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.74円
体外診断向け受託製造の市場規模、シェア、動向分析レポート：製品別、サービス別、技術別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2024年09月19日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

体外診断向け受託製造市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の体外診断向け受託製造市場規模は2030年までに374億5,000万米ドルに達する見込みです。

同市場は予測期間中にCAGR 10.04％で成長すると予測されています。

同市場は、診断機器に対する需要の高まり、ポイントオブケア診断の急増、分子検査の進歩、慢性疾患の有病率の増加などにより、有利な成長の可能性が見込まれています。さらに、費用対効果の高い製造、技術革新、診断薬に関する厳格な規制遵守に対するニーズの高まりが、市場の収益を押し上げると予想されます。そのため、ヘルスケア企業の間では、専門的な知識を利用し、生産を合理化し、市場投入までの時間を短縮するために、CMOやCDMOに製造サービスをアウトソーシングする傾向が強まっており、市場全体の成長を後押ししています。

体外診断用医薬品の自社製造にかかるコストが高いことは、市場成長を促進する大きな要因です。体外診断用医薬品の製造を開発し、規模を拡大するためには、インフラ、特殊機器、規制対応、熟練した労働力への高額な設備投資が必要であり、市場の成長を加速させる。こうした諸経費はリソースを圧迫し、中小規模の組織では収益性と柔軟性を低下させる。このため、CMOやCDMOに製造サービスをアウトソーシングすることで、企業は製造コストを削減し、社内設備投資の必要なく革新的な技術を利用できるようになります。さらに、アウトソーシングは市場参入の迅速化、拡張性の向上、リソースの最適化を可能にし、体外診断用医薬品市場における競争力を高める。

さらに、継続的な技術の進歩は、特に診断機器や検査ソリューションに対する市場需要を加速させる主な要因の一つです。分子診断、次世代シーケンシング（NGS）、自動化などの技術革新により、体外診断用医薬品の製造プロセスの精度、スピード、効率が向上しています。これらの進歩は、個別化医療、ポイントオブケア診断、より迅速な疾患検出法に対する需要の高まりに対応できるようメーカーを支援しています。さらに、AI主導の技術とデータ分析の統合は、製造ワークフローと品質保証プロセスを最適化し、精度と規制基準への準拠を強化します。さらに、多くのヘルスケア企業は、市場投入までの時間を短縮し、運用コストを削減し、製品の拡張性を高めるために、このような新しい技術にアクセスするために、受託製造業者とのコラボレーションに関与しています。このように、サービスプロバイダーによる先端技術の統合は、今後数年間の市場成長を促進すると推定されます。

体外診断向け受託製造市場のレポートハイライト

  • 製品別では、試薬・消耗品セグメントが2023年の売上高シェア69.34%で市場を独占しました。このセグメントの成長は、迅速診断ソリューションと個別化医療に対する需要の増加に起因しています。さらに、分子診断やポイントオブケア検査への嗜好の高まりが、専門的な試薬の必要性を高めています。さらに、自動化と次世代シーケンシング（NGS）の継続的な進歩が、高品質な消耗品の需要をさらに高めています。
  • サービス別では、製造サービス分野が2023年に最大のシェアを占めました。迅速で高品質な診断と個別化ヘルスケアソリューションへの需要の高まりが、スケールアップ生産への需要に拍車をかけ、受託サービス市場を拡大しています。また、費用対効果の高い生産と厳しい規制基準への準拠の必要性から、ヘルスケア企業はIVD市場の拡大するニーズに対応するため、製造のアウトソーシングを進めています。
  • 技術別では、イムノアッセイ分野が2023年に最大の収益シェアを占めました。この大きな収益シェアは、正確で迅速な診断検査に対する需要の高まりによるものです。さらに、慢性疾患の有病率の増加や個別化医療の重視の高まりが、同分野の成長を促進すると予測されています。さらに、バイオマーカー探索の革新とポイントオブケア診断の拡大が市場拡大を後押ししています。
  • 高度でカスタマイズ可能な診断ソリューションに対する需要の高まりと、精度を高めるためのデジタル技術の統合が、このセグメントの成長を加速する主な要因です。さらに、厳格な品質基準とサービスプロバイダーによる革新的な技術の統合が、医療機器メーカーによる革新的な能力と柔軟なソリューションを提供する受託製造業者との協業やパートナーシップを加速させ、拡大する市場ニーズに対応する主な要因となっています。
  • 北米は2023年に41.91%のシェアを獲得し、市場を独占しました。北米地域における慢性疾患の増加と高度な診断ソリューションへの需要が、市場拡大を後押ししています。また、費用対効果の高い製造ソリューションに対するニーズの高まりが、ヘルスケア企業の体外診断薬製造のアウトソーシングを促進しています。規制当局の支援と診断技術の革新が市場の勢いをさらに促進し、製造受託部門に成長と協力の機会を生み出しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 体外診断向け受託製造市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • テクノロジーの情勢
  • 業界エコシステム分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 体外診断向け受託製造市場：製品の推定・動向分析

  • 体外診断向け受託製造市場、製品別：セグメントダッシュボード
  • 体外診断向け受託製造市場、製品別：変動分析
  • 製品別、2018年-2030年
  • 機器
  • 試薬・消耗品
  • ソフトウェアとサービス

第5章 体外診断向け受託製造市場：サービスの推定・動向分析

  • 体外診断向け受託製造市場、サービス別：セグメントダッシュボード
  • 体外診断向け受託製造市場、サービス別：変動分析
  • サービス別、2018年-2030年
  • 製造サービス
  • アッセイ開発サービス
  • その他のサービス

第6章 体外診断向け受託製造市場：技術の推定・動向分析

  • 体外診断向け受託製造市場、技術別：セグメントダッシュボード
  • 体外診断向け受託製造市場、技術別：変動分析
  • 技術別、2018-2030年
  • 免疫測定
  • 臨床化学
  • 分子診断
  • 血液学
  • 微生物学
  • 凝固
  • その他

第7章 体外診断向け受託製造市場：最終用途の推定・動向分析

  • 体外診断向け受託製造市場、最終用途別：セグメントダッシュボード
  • 体外診断向け受託製造市場、最終用途別：変動分析
  • 最終用途別、2018年-2030年
  • 医療機器企業
  • 学術・調査機関
  • その他

第8章 体外診断向け受託製造市場：地域の推定・動向分析

  • 地域別市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 世界地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • デンマーク
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • タイ
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 市場参入企業の分類
    • マーケットリーダー
    • 新興プレーヤー
  • 企業市場シェア/評価分析、2023年
  • サービスヒートマップ分析、2023年
  • 企業プロファイル
    • Jabil Inc.
    • Sanmina Corporation
    • TE Connectivity
    • Celestica Inc.
    • Savyon Diagnostics
    • West Pharmaceutical Services, Inc.
    • Thermo Fisher Scientific
    • KMC Systems
    • Cenogenics Corporation
    • Novo Biomedical
    • Cone Bioproducts
    • Invetech
    • AVIOQ Inc.
    • Meridian Bioscience Inc.
    • Nemera
図表

List of Tables

  • Table. 1 Market segmentation
  • Table. 2 Market research process
  • Table. 3 Information procurement
  • Table. 4 Primary research pattern
  • Table. 5 Market research approaches
  • Table. 6 Value chain-based sizing & forecasting
  • Table. 7 QFD modelling for market share assessment
  • Table. 8 Market formulation & validation
  • Table. 9 In Vitro Diagnostics (IVD) contract manufacturing market revenue, 2018 - 2030 (USD Million)
  • Table. 10 In Vitro Diagnostics (IVD) contract manufacturing market snapshot
  • Table. 11 In Vitro Diagnostics (IVD) contract manufacturing market driver impact
  • Table. 12 In Vitro Diagnostics (IVD) contract manufacturing market restraint impact
  • Table. 13 In Vitro Diagnostics (IVD) contract manufacturing sector key takeaways (USD Million)
  • Table. 14 In Vitro Diagnostics (IVD) contract manufacturing Market: Product movement analysis
  • Table. 15 Instruments market, 2018 - 2030 (USD Million)
  • Table. 16 Reagents & consumables market, 2018 - 2030 (USD Million)
  • Table. 17 Software & services market, 2018 - 2030 (USD Million)
  • Table. 18 In Vitro Diagnostics (IVD) contract manufacturing market service key takeaways (USD Million)
  • Table. 19 In Vitro Diagnostics (IVD) contract manufacturing market: service movement analysis
  • Table. 20 Manufacturing services market, 2018 - 2030 (USD Million)
  • Table. 21 Assay development services market, 2018 - 2030 (USD Million)
  • Table. 22 Other services market, 2018 - 2030 (USD Million)
  • Table. 23 In Vitro Diagnostics (IVD) contract manufacturing market technology key takeaways (USD Million)
  • Table. 24 In Vitro Diagnostics (IVD) contract manufacturing market: technology movement analysis
  • Table. 25 Immunoassays market, 2018 - 2030 (USD Million)
  • Table. 26 Clinical chemistry market, 2018 - 2030 (USD Million)
  • Table. 27 Molecular diagnostics market, 2018 - 2030 (USD Million)
  • Table. 28 Hematology market, 2018 - 2030 (USD Million)
  • Table. 29 Microbiology market, 2018 - 2030 (USD Million)
  • Table. 30 Coagulation market, 2018 - 2030 (USD Million)
  • Table. 31 Others market, 2018 - 2030 (USD Million)
  • Table. 32 In Vitro Diagnostics (IVD) contract manufacturing market end use key takeaways (USD Million)
  • Table. 33 In Vitro Diagnostics (IVD) contract manufacturing market: end use movement analysis
  • Table. 34 Medical device companies' market, 2018 - 2030 (USD Million)
  • Table. 35 Academic & research institutions market, 2018 - 2030 (USD Million)
  • Table. 36 Others market, 2018 - 2030 (USD Million)
  • Table. 37 Regional marketplace: Key takeaways
  • Table. 38 Regional outlook, 2023 & 2030
  • Table. 39 North America In Vitro Diagnostics (IVD) contract manufacturing Market, 2018 - 2030 (USD Million)
  • Table. 40 U.S. In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 41 Canada In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 42 Mexico In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 43 Europe In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 44 UK In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 45 Germany In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 46 France In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 47 Italy In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 48 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Table. 49 Sweden In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 50 Denmark In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 51 Norway In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 52 Asia Pacific In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 53 Japan In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 54 China In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 55 India In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 56 Thailand In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 57 South Korea In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 58 Australia In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 59 Latin America In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 60 Brazil In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 61 Argentina In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 62 Middle East & Africa In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 63 South Africa In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 64 Saudi Arabia In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 65 UAE In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 66 Kuwait In Vitro Diagnostics (IVD) contract manufacturing market, 2018 - 2030 (USD Million)
  • Table. 67 Market participant categorization

List of Figures

  • Fig. 1 List of Tables
  • Fig. 2 List of Secondary Sources
  • Fig. 3 List of Abbreviations
  • Fig. 4 Global In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 5 Global In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 6 Global In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 7 Global In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 8 Global In Vitro Diagnostics (IVD) Contract Manufacturing, by Region, 2018 - 2030 (USD Million)
  • Fig. 9 North America In Vitro Diagnostics (IVD) Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Fig. 10 North America In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 11 North America In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 12 North America In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 13 North America In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 18 Canada In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 19 Canada In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 20 Canada In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 21 Canada In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 22 Mexico In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 23 Mexico In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 24 Mexico In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 26 Europe In Vitro Diagnostics (IVD) Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Fig. 27 Europe In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 28 Europe In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 29 Europe In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 30 Europe In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 31 Germany In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 32 Germany In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 33 Germany In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 34 Germany In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 35 UK In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 36 UK In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 37 UK In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 38 UK In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 39 France In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 40 France In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 41 France In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 42 France In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 43 Italy In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 44 Italy In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 45 Italy In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 46 Italy In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 47 Spain In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 48 Spain In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 49 Spain In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 50 Spain In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 55 Sweden In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 59 Norway In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 60 Norway In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 61 Norway In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 62 Norway In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific In Vitro Diagnostics (IVD) Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Fig. 64 Asia Pacific In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 66 Asia Pacific In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 68 China In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 69 China In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 70 China In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 71 China In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 72 Japan In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 73 Japan In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 74 Japan In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 75 Japan In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 76 India In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 77 India In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 78 India In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 79 India In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 80 South Korea In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 81 South Korea In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 82 South Korea In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 83 South Korea In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 84 Australia In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 85 Australia In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 86 Australia In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 87 Australia In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 88 Thailand In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 89 Thailand In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 90 Thailand In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 91 Thailand In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 92 Latin America In Vitro Diagnostics (IVD) Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Fig. 93 Latin America In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 94 Latin America In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 95 Latin America In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 96 Latin America In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 97 Brazil In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 98 Brazil In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 99 Brazil In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 100 Brazil In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 101 Argentina In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 102 Argentina In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 103 Argentina In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 104 Argentina In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 105 Middle East & Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Fig. 106 Middle East & Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 107 Middle East & Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 108 Middle East & Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 109 Middle East & Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 110 South Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 111 South Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 112 South Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 113 South Africa In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 114 Saudi Arabia In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 115 Saudi Arabia In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 116 Saudi Arabia In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 117 Saudi Arabia In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 118 UAE In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 119 UAE In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 120 UAE In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 121 UAE In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Fig. 122 Kuwait In Vitro Diagnostics (IVD) Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Fig. 123 Kuwait In Vitro Diagnostics (IVD) Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Fig. 124 Kuwait In Vitro Diagnostics (IVD) Contract Manufacturing, by Technology, 2018 - 2030 (USD Million)
  • Fig. 125 Kuwait In Vitro Diagnostics (IVD) Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-462-6

In Vitro Diagnostics Contract Manufacturing Market Growth & Trends:

The global in vitro diagnostics contract manufacturing market size is expected to reach USD 37.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.04% over the forecast period.

The market is anticipated to witness lucrative growth potential owing to rising demand for diagnostic devices, an upsurge in point-of-care diagnostics, advancements in molecular testing, and the increasing prevalence of chronic diseases. Moreover, the growing need for cost-effective manufacturing, technological innovation, and stringent regulatory compliance for diagnostics is expected to drive the market revenue stream. Thus, the increasing trend for outsourcing manufacturing services to CMOs and CDMOs to access specialized expertise, streamline production, and accelerate time-to-market among healthcare companies is boosting overall market growth.

The high cost of in-house IVD manufacturing is a significant driver propelling the market growth. The need for high capital investment in infrastructure, specialized equipment, regulatory compliance, and skilled workforce to develop and scale up IVD production will accelerate market growth. These overhead costs strain resources, reducing profitability and flexibility among several small and medium-scale organizations. Thus, by outsourcing manufacturing services to CMOs & CDMOs, companies can lower manufacturing costs and gain access to innovative technologies exclusive of the need for internal capital investment. Moreover, outsourcing allows faster market entry, enhanced scalability, and better resource optimization and offers a competitive edge in the IVD market.

Furthermore, continuous technological advancements are among the major factors accelerating the market demand, specifically for diagnostic devices and testing solutions. Innovations such as molecular diagnostics, next-generation sequencing (NGS), and automation have enhanced the accuracy, speed, and efficiency of IVD manufacturing processes. These advancements assist manufacturers to meet the increasing demand for personalized medicine, point-of-care diagnostics, and faster disease detection methods. Moreover, the integration of AI-driven technologies and data analytics optimizes production workflows and quality assurance processes, enhancing precision and compliance with regulatory standards. Furthermore, numerous healthcare companies are involved in collaboration with contract manufacturers to access such novel technologies to accelerate time-to-market, reduce operational costs, and enhance product scalability. Thus, the integration of advanced technologies by service providers is estimated to drive market growth in the forthcoming years.

In Vitro Diagnostics Contract Manufacturing Market Report Highlights:

  • Based on product, the reagents & consumables segment dominated the market with a revenue share of 69.34% in 2023. The segment growth is attributed to increasing demand for rapid diagnostic solutions and personalized medicine. Moreover, increasing preference for molecular diagnostics and point-of-care testing are boosting the need for specialized reagents. In addition, continuous advances in automation and next-generation sequencing (NGS) are further bolstering the demand for high-quality consumables.
  • Based on service, the manufacturing services segment held the largest share in 2023. The increasing demand for rapid, high-quality diagnostics and personalized healthcare solutions spurs the demand for scale-up production, thereby expanding the contract services market. In addition, the need for cost-effective production and compliance with stringent regulatory standards drives healthcare companies to outsource manufacturing to meet the growing needs of the IVD market.
  • Based on technology, the immunoassay segment accounted for the largest revenue share in 2023. This large revenue share is owing to the rising demand for accurate and rapid diagnostic tests. Moreover, the increasing prevalence of chronic diseases and a growing emphasis on personalized medicine is anticipated to drive segmental growth. In addition, innovations in biomarker discovery and the expansion of point-of-care diagnostics are propelling market expansion.
  • Based on end use, the medical device companies segment accounted for the largest revenue share in 2023.Growing demand for advanced, customizable diagnostic solutions and the integration of digital technologies for enhanced accuracy are key factors accelerating segment growth. Moreover, stringent quality standards and the integration of innovative technologies by service providers are major factors accelerating collaboration and partnerships by medical device companies with contract manufacturers that offer innovative capabilities and flexible solutions to meet growing market needs.
  • North America dominated the market with a share of 41.91% in 2023. The increasing prevalence of chronic diseases and the demand for advanced diagnostic solutions in the North American region are propelling market expansion. In addition, the rising need for cost-effective manufacturing solutions is leading healthcare companies to outsource IVD production. Regulatory support and innovation in diagnostic technologies further drive market momentum, creating opportunities for growth and collaboration within the contract manufacturing sector.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. In Vitro Diagnostics Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Industry Ecosystem Analysis
  • 3.5. Industry Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. In Vitro Diagnostics (Contract Manufacturing Market: Phases Estimates & Trend Analysis

  • 4.1. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Product: Segment Dashboard
  • 4.2. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Product: Movement Analysis
  • 4.3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Estimates & Forecasts, By Product, 2018 - 2030 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments Market, 2018 to 2030 (USD Million)
  • 4.5. Reagents & Consumables
    • 4.5.1. Reagents & Consumables Market, 2018 to 2030 (USD Million)
  • 4.6. Software & Services
    • 4.6.1. Software & Services Market, 2018 to 2030 (USD Million)

Chapter 5. In Vitro Diagnostics Contract Manufacturing Market: Service Estimates & Trend Analysis

  • 5.1. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Service: Segment Dashboard
  • 5.2. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Service: Movement Analysis
  • 5.3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Estimates & Forecasts, By Service, 2018 - 2030 (USD Million)
  • 5.4. Manufacturing Services
    • 5.4.1. Manufacturing Services Market, 2018 to 2030 (USD Million)
  • 5.5. Assay Development Services
    • 5.5.1. Assay Development Services Market, 2018 to 2030 (USD Million)
  • 5.6. Other Services
    • 5.6.1. Other Services Market, 2018 to 2030 (USD Million)

Chapter 6. In Vitro Diagnostics Contract Manufacturing Market: Technology Estimates & Trend Analysis

  • 6.1. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Technology: Segment Dashboard
  • 6.2. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Technology: Movement Analysis
  • 6.3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Estimates & Forecasts, By Technology, 2018-2030
  • 6.4. Immunoassays
    • 6.4.1. Immunoassays Market, 2018 to 2030 (USD Million)
  • 6.5. Clinical Chemistry
    • 6.5.1. Clinical Chemistry Market, 2018 to 2030 (USD Million)
  • 6.6. Molecular Diagnostics
    • 6.6.1. Molecular Diagnostics Market, 2018 to 2030 (USD Million)
  • 6.7. Hematology
    • 6.7.1. Hematology Market, 2018 to 2030 (USD Million)
  • 6.8. Microbiology
    • 6.8.1. Microbiology Market, 2018 to 2030 (USD Million)
  • 6.9. Coagulation
    • 6.9.1. Coagulation Market, 2018 to 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market, 2018 to 2030 (USD Million)

Chapter 7. In Vitro Diagnostics Contract Manufacturing Market: End Use Estimates & Trend Analysis

  • 7.1. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By End Use: Segment Dashboard
  • 7.2. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By End Use: Movement Analysis
  • 7.3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 - 2030 (USD Million)
  • 7.4. Medical Device Companies
    • 7.4.1. Medical Device Companies Market, 2018 to 2030 (USD Million)
  • 7.5. Academic & Research Institutions
    • 7.5.1. Academic & Research Institutions Market, 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 to 2030 (USD Million)

Chapter 8. In Vitro Diagnostics Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Thailand
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Australia
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Company Market Share/Assessment Analysis, 2023
  • 9.3. Service Heat Map Analysis, 2023
  • 9.4. Company Profiles
    • 9.4.1. Jabil Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Service Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Sanmina Corporation
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Service Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. TE Connectivity
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Service Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Celestica Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Service Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Savyon Diagnostics
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Service Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. West Pharmaceutical Services, Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Service Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Thermo Fisher Scientific
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Service Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. KMC Systems
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Service Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Cenogenics Corporation
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Service Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Novo Biomedical
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Service Benchmarking
      • 9.4.10.4. Strategic Initiatives
    • 9.4.11. Cone Bioproducts
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Service Benchmarking
      • 9.4.11.4. Strategic Initiatives
    • 9.4.12. Invetech
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Service Benchmarking
      • 9.4.12.4. Strategic Initiatives
    • 9.4.13. AVIOQ Inc.
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Service Benchmarking
      • 9.4.13.4. Strategic Initiatives
    • 9.4.14. Meridian Bioscience Inc.
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Financial Performance
      • 9.4.14.3. Service Benchmarking
      • 9.4.14.4. Strategic Initiatives
    • 9.4.15. Nemera
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Financial Performance
      • 9.4.15.3. Service Benchmarking
      • 9.4.15.4. Strategic Initiatives